Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR
April 16th, 2008
Dr. Roger Kenneth Hershline, PhD, MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces that he is reaching out to the funder community, including funding initiatives such as the Grand Challenges in Global Health initiative. The monies would be used to begin clinical studies of a new drug and treatment method, LiSAVIOR. This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on...
Source: Vaccine Weekly (2008-04-16)
|
